Disclosed herein are extended release pharmaceutical compositions comprising minocycline and pharmaceutically acceptable salts thereof and a process for preparing the composition thereof. The extended release pharmaceutical composition comprises minocycline or pharmaceutically acceptable salt thereof, a rapid dissolving component (s), a slow dissolving component (s) and optionally other pharmaceutically acceptable excipients.
A01N 37/18 - Biocides, produits repoussant ou attirant les animaux nuisibles, ou régulateurs de croissance des végétaux, contenant des composés organiques comportant un atome de carbone possédant trois liaisons à des hétéro-atomes, avec au plus deux liaisons à un halogène, p. ex. acides carboxyliques contenant le groupe —CO—N, p. ex. amides ou imides d'acide carboxyliqueLeurs thio-analogues
Disclosed herein is a stabilized sustained release pharmaceutical composition of bupropion hydrochloride and process for preparing the same, wherein said pharmaceutical composition comprising therapeutically effective amount of uncoated fine bupropion hydrochloride and pharmaceutically acceptable adjuvants, and wherein the composition is free of an acidic stabilizer and contains less than about 0.3% by weight of m-chlorobenzoic acid.
Disclosed herein is an extended release pharmaceutical composition comprising at least two populations of extended release minitablets having a core comprising carbamazepine or its pharmaceutical salts, solvates, hydrates, an extended release polymer(s), wherein the extended release polymer of each population of minitablets is unalike. The process for manufacturing said composition is also disclosed.
A61K 9/22 - Pilules, pastilles ou comprimés du type à libération prolongée ou discontinue
4.
PROCESS FOR PRODUCING 6(R)-[2-(8'(S)-2 ',2 '-DIMETHYLBUTYRYLOXY-2'(S),6'(R)-DIMETHYL-1,2,6,7', 8',8A'(R)- HEXAHYDRONAPHTHYL-L'(S))ETHYL]-4(R)-HYDROXY-3,4,5,6- TETRAHYDRO-2H-PYRAN-2-ONE
Disclosed herein is an improved process for producing HMG-CoA reductase inhibitor, 6(R)-[2-(8 '(S)-2 ',2 ''-dimethylbutyryloxy-2'(S),6 '(R)-dimethyl- 1', 2', 6', 7', 8',8a'(R)-hexahydronaphthyl-r(S))ethyl]-4(R)-hydroxy-3,4,5,6-tetrahydro-2H- pyran-2-one, the process comprising hydrolyzing (lS,3R,7S,8S,8aR)-8-{2-[(2R,4R)- 4-hydroxy-6-oxotetrahydro-2H-ρyran-2-yl]ethyl}-3,7-dimethyl-l,2,3,7,8,8a- hexahydronaphthalen-1-yl (2S)-2-methylbutanoate in presence of a base and antioxidant, lactonizing and selectively protecting the hydroxyl group of the resultant compound, followed by acylation with an acylating agent to obtain 6(R)-[2-(8'(S)- 2',2''-dimethylbutyryloxy-2 '(S),6 '(R)-dimethyl- 1',2',6',7',8',8a'(R)- hexahydronaphthyl-r(S))ethyl]-4(R)-substituted)-3,4,5,6-tetrahydro-2H-pyran-2-one and further deprotection to obtain 6(R)-[2-(8'(S)-2',2'-dimethylbutyryloxy- 2'(S),6'(R)-dimethyl-1',2',6',7',8',8a'(R)-hexahydronaphthyl-1'(S))ethyl]-4(R)- hydroxy-3,4,5,6-tetrahydro-2H-pyran-2-one.
Disclosed herein an extended release pharmaceutical formulation of the propranolol hydrochloride comprising a core and an extended release coating on said core wherein said core comprising said propranolol hydrochloride and one ore more pharmaceutically acceptable excipients and coating comprising extended release polymers in an amount of about 1 to about 5% by weight based on the total weight of the core.
Disclosed herein a water dispersible compressed tablet and process for preparing the same. The tablet comprising about 0.1 to 50% w/w of lamotrigine or its pharmaceutically acceptable salts, solvates, hydrates or polymorphs, about 5 to about 50% w/w of a water-soluble diluent (s), about 15 to about 70 % w/w of a water swellable diluent (s), optionally one or more pharmaceutically acceptable adjuvants, wherein the ratio of water-soluble diluent(s) to water swellable diluent(s) is from about 0.6 to about 0.9 and said composition is essentially free of disintegrant, superdisintegrant and swellable clay.
Disclosed herein novel crystalline polymorphic forms of 1-benzyl-4-(5,6-dimethoxy-1-indanon-2-yl)methylpiperidine (Donepezil) base having higher stability. Said polymorphic forms are designated as Form D and E and characterized by employing analytical tools such as infrared absorption spectrum, X-ray powder diffraction pattern, thermo gravimetric analysis (TGA), differential scanning calorimetry (DSC) and/or melting point. The present invention also disclosed a process for preparing said polymorphic forms. Further an improved process for preparing polymorphic form B of 1-benzyl-4-(5,6-dimethoxy-1-indanon-2-yl)methylpiperidine (Donepezil) base is also disclosed.
C07D 211/32 - Composés hétérocycliques contenant des cycles pyridiques hydrogénés, non condensés avec d'autres cycles avec uniquement des atomes d'hydrogène et de carbone liés directement à l'atome d'azote du cycle ne comportant pas de liaison double entre chaînons cycliques ou entre chaînons cycliques et chaînons non cycliques avec des radicaux hydrocarbonés ou des radicaux hydrocarbonés substitués, liés directement aux atomes de carbone du cycle avec des radicaux hydrocarbonés substitués liés aux atomes de carbone du cycle avec des radicaux hydrocarbonés, substitués par des atomes d'oxygène ou de soufre liés par des liaisons doubles ou par deux atomes d'oxygène ou de soufre, liés au même atome de carbone par des liaisons simples par des atomes d'oxygène
8.
ECO-FRIENDLY PROCESS FOR RECOVERY OF PYRIDINE AND/OR ITS DERIVATIVES
Disclosed herein is a process for recovery of pyridine and/or its derivatives from their aqueous mass and/ or manufacturing reaction mass by liquid-liquid extraction employing an environmentally non-hazardous organic solvent. The process further comprising effective recovering and recycle of solvents from the aqueous phase and the other waste obtained during the process.
C07D 213/06 - Composés hétérocycliques contenant des cycles à six chaînons, non condensés avec d'autres cycles, ne comportant qu'un atome d'azote comme unique hétéro-atome du cycle et avec au moins trois doubles liaisons entre chaînons cycliques ou entre chaînons cycliques et chaînons non cycliques comportant trois liaisons doubles ne comportant pas de liaison entre l'atome d'azote du cycle et un chaînon non cyclique ou ne comportant que des atomes d'hydrogène ou de carbone liés directement à l'atome d'azote du cycle contenant uniquement des atomes d'hydrogène et de carbone en plus de l'atome d'azote du cycle
9.
MODIFIED RELEASE PHARMACEUTICAL COMPOSITION OF BUPROPION HYDROCHLORIDE
A delayed extended release pharmaceutical composition includes a compressed core containing an effective amount of bupropion or its pharmaceutically acceptable salt, a water-attractant polymer. The core is preferably devoid of a stabilizer. The core is surrounded by an extended release layer, which is free of plasticizer and pore-forming agent. The extended release layer is surrounded by a delayed release layer. Alternating coats of extended release layer and delayed release layer may follow. A preferred extended release layer includes ethylcellulose and hydroxypropyl cellulose or hydroxypropyl methylcellulose and a preferred delayed release layer includes methacrylic acid copolymer and hydroxypropyl methylcellulose phthalate, lactose and a combination of triethyl citrate and polyethylene glycol and talc. A method of preparing the delayed extended release bupropion hydrochloride containing pharmaceutical composition is also disclosed.
Disclosed herein, a process for producing sulphoxide compound of the Formula (I) by asymmetrically oxidizing a prochiral sulphide of the Formula (II) with an effective amount of oxidizing agent in the presence of a chiral transition metal complex without using an organic solvent and base.
C07D 401/12 - Composés hétérocycliques contenant plusieurs hétérocycles comportant des atomes d'azote comme uniques hétéro-atomes du cycle, au moins un cycle étant un cycle à six chaînons avec un unique atome d'azote contenant deux hétérocycles liés par une chaîne contenant des hétéro-atomes comme chaînons
11.
PROCESS FOR PRODUCING 10-OXO-L10, 11-DIHYDR0-5H-DIBENZ [B, F] AZEPINE-5-CARBOXAMIDE STARTING FROM 5-CYANOIMINOSTILBENE
Disclosed herein is a process for producing 10-oxo-10,11-dihydro-5H-dibenz[bf ] azepine-5-carboxamide of formula I via novel intermediates 11-alkoxy-10-halo-10,11-dihydro-5H-dibenzo [b,f ] azepine-5-carbonitrile [XIX] or 10-alkoxy-5H-dibenz [b,f] azepine -5-carbonitrile [XX]. Further the present invention also provides a process for preparation of said intermediates.
C07D 223/26 - Dibenz [b, f] azépinesDibenz [b, f] azépines hydrogénées avec des radicaux hydrocarbonés, substitués par des atomes d'azote, liés à l'atome d'azote du cycle comportant une liaison double entre les positions 10 et 11
C07D 223/28 - Dibenz [b, f] azépinesDibenz [b, f] azépines hydrogénées avec des radicaux hydrocarbonés, substitués par des atomes d'azote, liés à l'atome d'azote du cycle comportant une liaison simple entre les positions 10 et 11
12.
PROCESS FOR STABILIZATION OF OLANZAPINE POLYMORPHIC FORM I
Disclosed herein a process for stabilization of polymorphic Form I of olanzapine. Said process comprises of micronizing said olanzapine in a fluid energy mill employing nitrogen or carbon dioxide.
Disclosed herein is an economically viable and cost effective process for preparation of oxcarbazepine of formula (I) via a novel intermediate of formula (XVIII).
A solid dispersion or premix product comprising an effective amount of an active ingredients and an effective amount of one or more hydrophilic polymers wherein the solid dispersion product can either be a co-precipitate or a co-evaporate. The solid dispersion or premix product is used for the manufacture of a dosage form having improved bioavailability of said one or more active ingredients by oral administration to a patient in need thereof.
A61K 31/55 - Composés hétérocycliques ayant l'azote comme hétéro-atome d'un cycle, p. ex. guanéthidine ou rifamycines ayant des cycles à sept chaînons, p. ex. azélastine, pentylènetétrazole
A61K 47/34 - Composés macromoléculaires obtenus par des réactions autres que celles faisant intervenir uniquement des liaisons non saturées carbone-carbone, p. ex. polyesters, acides polyaminés, polysiloxanes, polyphosphazines, copolymères de polyalkylène glycol ou de poloxamères
Disclosed herein an extended release pharmaceutical formulation of venlafaxine comprising venlafaxine or its pharmaceutical acceptable salts in the form of spheroids. Said spheroids having a core consisting of about 40 % to about 55 % by weight of venlafaxine hydrochloride, about 40 % to about 50 % by weight of microcrystalline cellulose, about 0.5 % to about 5% by weight of hydroxypropyl methylcellulose, wherein the core is coated employing a combination of water insoluble and water soluble polymers.
Disclosed herein a taste masked pharmaceutical composition suitable for oral solid dosage form comprising adsorbate of unpleasant or objectionable tasting active pharmaceutical agents and water insoluble polymer, wherein said active is first blended with an adsorbent such as magnesium aluminium silicate to achieve partially or significantly taste masking of said active and further granulated the resultant blend with water insoluble polymer to strengthen the taste masking without affecting the release of said active.
Disclosed is an improved process for producing pure and thermally color stable crystalline Form I of 2-methyl-4-(4-methyl-l-piperazinyl)-10H-thieno⏧2,3-b]⏧l,5] benzodiazepine and product thereof. The process comprises of reacting 2-(2- aminoanilino)-5-methylthiophene-3-carbonitrile with N-methyl piperazine in conjunction with N-methylpiperazine acid salt, to produce 2-methyl-4-(4-methyl-l- piperazinyl)-10H-thieno⏧2,3-b]⏧l,5] benzodiazepine. Also disclosed is a process for obtaining the Polymorphic Form I of 2-methyl-4-(4-methyl-l-piperazinyl)-10H- thieno⏧2,3-b]⏧l ,5J benzodiazepine by crystallizing the crude 2-methyl-4-(4-methyl-l- piperazinyl)-10H-thieno ⏧2,3-b]⏧l ,5] benzodiazepine in a mixture of solvents. Further the invention also provides a new polymorph of Olanzapine, dihydrate Form Ji and process for its preparation and a new hydrate Form J2 of Olanzapine having moisture content 1 -3% and process for its preparation.
Disclosed herein is an extended release pharmaceutical formulation suitable for once daily administration, comprising a highly water soluble core consisting essentially of about 30 to about 40 % by weight of venlafaxine hydrochloride, about 50 to about 80 % by weight of water soluble diluent and about 2 to about 10% of water soluble binder and a coating layer having an effective combination of rate controlling polymers comprising water-soluble polymer and water insoluble, water permeable polymer.
Disclosed is a novel process for preparing pure amorphous form of Atorvastatin employing a suitable solvent system selected from water, water miscible solvents or water immiscible solvents or mixture thereof.
C07D 207/00 - Composés hétérocycliques contenant des cycles à cinq chaînons, non condensés avec d'autres cycles, ne comportant qu'un atome d'azote comme unique hétéro-atome du cycle
A process for preparing substituted sulphoxide using asymmetric oxidation of a pro-chiral sulphide employing a novel enantioselective agent along with oxidizing agents optionally in presence of an organic solvent, wherein said enantioselective agents is chiral transition metal complex or chiral dioxiranes. The chiral ligand used in this process is selected from dicyclohexylidene or diacetonide or substituted or unsubstituted benzylidene derivatives of sugars.
C07D 401/12 - Composés hétérocycliques contenant plusieurs hétérocycles comportant des atomes d'azote comme uniques hétéro-atomes du cycle, au moins un cycle étant un cycle à six chaînons avec un unique atome d'azote contenant deux hétérocycles liés par une chaîne contenant des hétéro-atomes comme chaînons
21.
STABLE PHARMACEUTICAL FORMULATION OF AN ACID LABILE COMPOUND AND PROCESS FOR PREPARING THE SAME
The disclosed invention provides oral pharmaceutical formulations of an acid labile benzimidazole derivative comprising (a) a core comprising an acid labile benzimidazole derivative, (b) a seal coating layer, and (c) an enteric coating layer, wherein the core of the composition is devoid of any disintegrant.
Disclosed herein is a orally disintegrating and/or dissolving oral pharmaceutical composition, comprising one or more active pharmaceutical ingredients, one or more fillers having particle size of 100 microns or above, a high and desirable amount of silicon dioxide, one or more disintegrating agents, optionally effervescent couple, wherein said composition has good organoleptic properties like desired mouth feel and fast oral disintegration time.
A61K 31/167 - Amides, p. ex. acides hydroxamiques ayant des cycles aromatiques, p. ex. colchicine, aténolol, progabide ayant l'atome d'azote d'un groupe carboxamide lié directement au cycle aromatique, p. ex. lidocaïne, paracétamol
A61K 31/445 - Pipéridines non condensées, p. ex. pipérocaïne
A61K 31/54 - Composés hétérocycliques ayant l'azote comme hétéro-atome d'un cycle, p. ex. guanéthidine ou rifamycines ayant des cycles à six chaînons avec au moins un azote et au moins un soufre comme hétéro-atomes d'un cycle, p. ex. sulthiame
A61K 31/551 - Composés hétérocycliques ayant l'azote comme hétéro-atome d'un cycle, p. ex. guanéthidine ou rifamycines ayant des cycles à sept chaînons, p. ex. azélastine, pentylènetétrazole ayant deux atomes d'azote comme hétéro-atomes d'un cycle, p. ex. clozapine, dilazèpe
brevets